Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...

Celltrion will establish a CRDMO subsidiary in Korea by the end of this year and first build a production facility with a ...

We are initiating coverage of biosimilar manufacturer Celltrion. Its current flagship drugs include biosimilars to Remicade, Rituxan, Herceptin, and Avastin. The bottom line: We initiate with a ...

Celltrion has finally merged with Celltrion Healthcare, three years after its original plan was announced. Celltrion announced that its board had approved the merger on Thursday. Each share of ...

Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers ...

TORONTO, March 27, 2025--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...

Celltrion, which completed its merger with Celltrion Healthcare in December last year, had been set to merge with Celltrion Pharm, the drugmaker’s domestic distributor and chemical drug development ...

Celltrion recently confirmed that it proved the effectiveness of its subcutaneous infliximab biosimilar, RemsimaSC (CT-P13 SC) in two global Phase III trials. The Phase III study was a 54-week ...